Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients

Khushnuma Wahabi; Ahmad Perwez; Shabeena Kamarudheen; Zafar Iqbal Bhat; Anurag Mehta; M. Moshahid A. Rizvi

doi:10.1186/s12885-019-6013-6

Table 2 Correlation of Parkin protein expression with clinical parameters among breast cancer patients

From: Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients

S. No.	Variables		Total	Parkin Expression^a		P value^b	OR (95%CI)
S. No.	Variables		Total	Positive	Negative	P value^b	OR (95%CI)
1	Age (Years)	< 50	30	9 (30)	21 (70)	0.832	1.1255(0.4738–2.6737)
1	Age (Years)	≥50	126	41 (33)	85 (67)	0.832	1.1255(0.4738–2.6737)
2	Weight (Kg)	< 60	75	26 (35)	49 (65)	0.607	0.7935 (0.4046–1.5562)
2	Weight (Kg)	≥60	81	24 (30)	57 (70)	0.607	0.7935 (0.4046–1.5562)
3	Tumour size (cm)	< 4’	73	29 (40)	44 (60)	0.060	0.5139 (0. 2599–1.0161)
3	Tumour size (cm)	≥4	83	21 (25)	62 (75)	0.060	0.5139 (0. 2599–1.0161)
4	Clinical Stage	I + II	88	29 (33)	59 (67)	0.863	0.9090 (0.4606–1.7941)
4	Clinical Stage	III + IV	68	21 (31)	47 (69)	0.863	0.9090 (0.4606–1.7941)
5	Histological^c grade	WD	54	27 (50)	27 (50)	0.0001*	0.2911 (0.1435–0.5906)
5	Histological^c grade	MD + PD	102	23 (22)	79 (78)	0.0001*	0.2911 (0.1435–0.5906)
6	Lymph Node	Negative	81	39 (48)	42 (52)	< 0.0001*	0.1851 (0.0854–0.4014)
6	Lymph Node	Positive	75	11 (15)	64 (85)	< 0.0001*	0.1851 (0.0854–0.4014)
7	Menopause	Pre	38	18 (47)	20 (53)	0.028*	0.4134 (0.1943–0.8797)
7	Menopause	Post	118	32 (27)	86 (73)	0.028*	0.4134 (0.1943–0.8797)
8	ER^d	Negative	81	23 (28)	58 (72)	0.391	1.9438 (0.0190–3.7081)
8	ER^d	Positive	75	27 (36)	48 (64)	0.391	1.9438 (0.0190–3.7081)
9	PR^e	Negative	103	32 (31)	71 (69)	0.721	1.1411 (0.5637–2.3099)
9	PR^e	Positive	53	18 (34)	35 (66)	0.721	1.1411 (0.5637–2.3099)
10	Her-2^f	Negative	111	36 (32)	75 (68)	1.000	0.9409 (0.4463–1.9835)
10	Her-2^f	Positive	45	14 (31)	31 (69)	1.000	0.9409 (0.4463–1.9835)
11	TNBC^g	No	106	42 (40)	64 (60)	0.003*	0.2902 (0.1240–0.6793)
11	TNBC^g	Yes	50	8 (16)	42 (84)	0.003*	0.2902 (0.1240–0.6793)

^a Protein expression through IHC (Immunohistochemistry)
^b Fisher’s exact test, *Significant Correlation (P < 0.05)
^c WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated
^d Estrogen receptor
^e Progesterone receptor
^f human epidermal growth factor receptor 2
^g Triple Negative breast cancer

Back to article page